| Recruiting | A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chroni Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | 2025-01-03 |
| Withdrawn | A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Scleros Relapsing Multiple Sclerosis, Multiple Sclerosis | Phase 2 | 2024-05-01 |
| Recruiting | A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/S Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell | Phase 3 | 2022-07-22 |
| Completed | A Study of the Effect of Food on Selpercatinib (LY3527723) in Healthy Participants Healthy | Phase 1 | 2022-04-19 |
| Completed | A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LY3527727) and Rosuvastatin in Healthy Participants Healthy | Phase 1 | 2022-01-11 |
| Completed | A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy Participants Healthy | Phase 1 | 2021-12-03 |
| Completed | A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy Participants Healthy | Phase 1 | 2021-10-29 |
| Active Not Recruiting | A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | 2021-09-23 |
| Active Not Recruiting | A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) i Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | 2021-09-20 |
| Active Not Recruiting | Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL Lymphoma, Mantle-Cell | Phase 3 | 2021-04-08 |
| Active Not Recruiting | Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | 2021-03-09 |
| Completed | A Drug Drug Interaction (DDI) Study of Selpercatinib and Dabigatran in Healthy Participants Healthy | Phase 1 | 2021-03-05 |
| Completed | Study of the Effects of Itraconazole and Rifampin on LOXO-305 in Healthy Participants Healthy Volunteers | Phase 1 | 2020-02-12 |
| Active Not Recruiting | A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer Medullary Thyroid Cancer | Phase 3 | 2020-02-11 |
| Completed | Study of the Effect of Food and a Proton Pump Inhibitor (PPI; Omeprazole) on LOXO-305 in Healthy Participants Healthy Volunteers | Phase 1 | 2020-02-06 |
| Completed | A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma | Phase 1 / Phase 2 | 2019-03-15 |
| Approved For Marketing | Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Lymphocytic, Small, Lymphoma, Mantle-Cell | — | — |